Physician profile
Robin Wong
NPI 1255383683
$11,340.54
in general payments reported to CMS, 2019-2025
25 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,428 · 2020: $1,738 · 2021: $2,251 · 2022: $2,113 · 2023: $1,499 · 2024: $881 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,825.93 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,698.15 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $1,607.24 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,385.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,005.30 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $992.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $473.94 | 2021-2025 | |
| Amgen INC. | $441.01 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $390.45 | 2019-2025 | |
| Amarin Pharma, INC. | $282.68 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $274.74 | 2019-2022 | |
| Exact Sciences Corporation | $175.79 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.15 | 2020-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $148.24 | 2020-2022 | |
| Abbvie INC. | $97.38 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $83.17 | 2019-2025 | |
| Allergan, INC. | $61.11 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $42.71 | 2023-2024 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $39.51 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $30.82 | 2021 | |
| Astellas Pharma US INC | $26.47 | 2024 | Veozah |
| Medtronic, INC. | $25.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.71 | 2023 | Eliquis |
| Dermira, INC. | $17.90 | 2020 | |
| Silk Road Medical, INC. | $17.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.